Visceral adipose tissue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Hypersensitivity to methocarbamol or any of the injection components. For the injectable form, suspected kidney failure or renal pathology, due to large content of polyethylene glycol 300 that can increase pre-existing acidosis and urea retention.
Side effects of diacetyldihydromorphine are similar to those of other semi-synthetic opiates and fully synthetic opioids, and the most commonly reported side effects include drowsiness, nausea, and constipation. Compared to morphine, diacetyldihydromorphine produces far fewer side effects which are also often lower in intensity. Though the two drugs are very similar in effects, morphine often produces more intense side effects, including euphoria, constipation, miosis, physical dependence, psychological dependence, potentially life-threatening respiratory depression, and a severe addiction. Illicit synthesis of dihydroheroin from morphine has been reported, and a "cook" interviewed for a National Geographic documentary on drugs in Vancouver lists it, along with hydromorphone, heroin and 4-methylaminorex (a stimulant) amongst the products he prepares.
=== Local boards and sanitary districts === Outside of municipal boroughs, there was no effective local government until the 1840s. In response to poor sanitary conditions and outbreaks of cholera, the Public Health Act 1848 (11 & 12 Vict. c. 63) and the Local Government Act 1858 allowed for the formation of local boards of health in populous areas. Local boards were responsible among other things for water supply, drainage, sewerage, paving and cleansing. Eleven local boards were initially formed at Brampton, Cleator Moor, Cockermouth, Egremont, Holme Cultram, Keswick, Maryport, Millom, Penrith, Whitehaven, Wigton and Workington. Further reform under the Public Health Act 1875 (38 & 39 Vict. c. 55) saw the creation of sanitary districts throughout England and Wales. The existing municipal boroughs and local boards became "urban sanitary districts", while "rural sanitary districts" were formed from the remaining areas of the poor law unions. Three more local boards were formed: Arlecdon and Frizington in 1882, Harrington in 1891 and Aspatria in 1892. In addition Workington and Whitehaven received charters of incorporation to become municipal boroughs in 1883 and 1894 respectively.
=== Electronation and de-electronation === The electrochemist John Bockris proposed the words electronation and de-electronation to describe reduction and oxidation processes, respectively, when they occur at electrodes. These words are analogous to protonation and deprotonation. IUPAC has recognized the terms electronation and de-electronation.
Sources: en.wikipedia.org
== Function == PAPPA encodes a secreted metalloproteinase which cleaves insulin-like growth factor–binding proteins (IGFBPs). PAPPA's proteolytic function is activated upon collagen binding. It is thought to be involved in local proliferative processes such as wound healing and bone remodeling. Low plasma level of this protein has been suggested as a biochemical marker for pregnancies with aneuploid fetuses (fetuses with an abnormal number of chromosomes). For example, low PAPPA may be commonly seen in prenatal screening for Down syndrome. Low levels may alternatively predict issues with the placenta, resulting in adverse complications such as intrauterine growth restriction, preeclampsia, placental abruption, premature birth, or fetal death. This enzyme catalyses the following chemical reaction: Cleavage of the Met135-Lys bond in insulin-like growth factor binding protein (IGFBP)-4, and the Ser143-Lys bond in IGFBP-5 This enzyme belongs to the peptidase family M43.
=== Cancer-related === Translationally controlled tumor protein has a role in tumor reversion and development. TCTP is a regulator of the cancer stem cell compartment, the tumor reversion, tumor progression and certain forms of inflammatory diseases. Moreover, TCTP was described as a pro-survival protein antagonizing BAX function.
== Supplement use and research == Grape seed extract is sold as a dietary supplement. Oral administration of grape seed extract (dose and frequency unreported) was well tolerated in people over 14 weeks. Side effects may include itchy scalp, dizziness, headache, and nausea. A 2019 meta-analysis suggested that grape seed extract might help to lower concentrations of LDL cholesterol, total cholesterol, triglycerides, and the inflammatory marker, C-reactive protein. However, each of the studies was small in size, possibly affecting interpretation of the analysis. A 2016 meta-analysis concluded that grape seed extract, in a dose of under 800 milligrams per day over at least 8 weeks, might help to reduce systolic and diastolic blood pressure. People with metabolic syndrome had a more significant outcome (average of a 8½ mmHg decrease in systolic blood pressure) than in healthy subjects. The authors concluded that heterogeneity in the study designs and small sample sizes involved in the meta-analysis introduced uncertainty in the results, and that larger-scale, long-term, multiple-dose studies in people with high blood pressure were warranted.
=== Assessment and physical examination === Catatonia is often overlooked and under-diagnosed. Most patients present with an underlying psychiatric disorder, which can obscure recognition of catatonia. For example, psychotic symptoms may dominate the clinical picture, while classic catatonic features (such as mutism or posturing) are absent. Motor abnormalities can also be misleading; in mania, increased motor activity is typically goal-directed, whereas in excited catatonia, activity is non–goal-directed and repetitive. Careful observation of motor behavior is therefore crucial for diagnosis. Catatonia remains a clinical diagnosis with no specific laboratory test to diagnose it. However, supportive investigations may help identify underlying causes:
==== Other early Americans ==== American officer John Parker Boyd partook in the Battle of Kharda, fighting on the side of the Nizam of Hyderabad. American Founding Father Aaron Burr had a relationship with an East Indian woman named Mary Emmons, who was most likely from the Indian city of Calcutta. Together, they had two children, including John Pierre Burr. Dudley Leavitt Pickman was an early American trader with India who founded the East India Marine Society. Fitzedward Hall was the first American to edit a Sanskrit text.
Sources: en.wikipedia.org
== Medical uses == Arsenic trioxide has emerged as a therapeutic agent in cancer treatment, especially for acute promyelocytic leukemia (APL). It achieves high remission rates, including among patients with relapsed disease, and offering advantages over other treatments like bone marrow transplantation and all-trans retinoic acid (ATRA), particularly by reducing toxicity and improving patient outcomes. The combined regimen of arsenic trioxide with ATRA is now considered a standard of care for newly diagnosed and relapsed APL, showing substantial efficacy even in pediatric and elderly populations. Arsenic trioxide is intended for the induction of remission and consolidation in adult patients with acute promyelocytic leukemia who have the t(15;17) translocation and/or the fusion of PML and RARα genes. The drug should be used after treatment failure or relapse. Prior therapy should include retinoid and chemotherapy. The current standard of care for acute promyelocytic leukemia (APL) is risk-adapted therapy based on the patient’s white blood cell count at diagnosis. For patients with non-high-risk APL (typically defined as a white blood cell count ≤10,000/μL), the preferred treatment is a chemotherapy-free regimen that combines all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), which has demonstrated superior efficacy and a favorable safety profile compared to regimens that include chemotherapy.
==== Endothelial keratoplasty ==== Endothelial keratoplasty replaces the patient's endothelium with a transplanted disc of posterior stroma/Descemets/endothelium (DSEK) or Descemets/endothelium (DMEK). This relatively new procedure has revolutionized treatment of disorders of the innermost layer of the cornea (endothelium). Unlike a full-thickness corneal transplant, the surgery can be performed with one or no sutures. Patients may recover functional vision in days to weeks, as opposed to up to a year with full thickness transplants. However, an Australian study has shown that despite its benefits, the loss of endothelial cells that maintain transparency is much higher in DSEK compared to a full-thickness corneal transplant. The reason may be greater tissue manipulation during surgery, the study concluded. During surgery the patient's corneal endothelium is removed and replaced with donor tissue. With DSEK, the donor includes a thin layer of stroma, as well as endothelium, and is commonly 100–150 μm thick. With DMEK, only the endothelium is transplanted. In the immediate postoperative period the donor tissue is held in position with an air bubble placed inside the eye (the anterior chamber). The tissue self-adheres in a short period and the air is adsorbed into the surrounding tissues. Complications include displacement of the donor tissue requiring repositioning ("refloating"). This is more common with DMEK than DSEK. Folds in the donor tissue may reduce the quality of vision, requiring repair. Rejection of the donor tissue may require repeating the procedure.
An organic compound is a chemical whose molecules contain carbon. Carbon is abundant in the Sun, stars, comets, and in the atmospheres of most planets of the Solar System. Organic compounds are relatively common in space, formed by "factories of complex molecular synthesis" which occur in molecular clouds and circumstellar envelopes, and chemically evolve after reactions are initiated mostly by ionizing radiation. Purine and pyrimidine nucleobases including guanine, adenine, cytosine, uracil, and thymine, as well as sugars, have been found in meteorites. These could have provided the materials for DNA and RNA to form on the early Earth. The amino acid glycine was found in material ejected from comet Wild 2; it had earlier been detected in meteorites. Comets are encrusted with dark material, thought to be a tar-like organic substance formed from simple carbon compounds under ionizing radiation. A rain of material from comets could have brought such complex organic molecules to Earth. During the Late Heavy Bombardment, meteorites may have delivered up to five million tons of organic prebiotic elements to Earth per year. Currently 40,000 tons of cosmic dust falls to Earth each year.
The ambassador from the Netherlands explained his negative vote as being due to the reference in the preamble to the resolution "to potential harmful effects of the use of depleted uranium munitions on human health and the environment [which] cannot, in our view, be supported by conclusive scientific studies conducted by relevant international organizations." None of the other permanent members of the United Nations Security Council supported the resolution as China was absent for the vote, Russia abstained and the United States voted against the resolution. In September 2008, and in response to the 2007 General Assembly resolution, the UN Secretary General published the views of 15 states alongside those of the International Atomic Energy Agency (IAEA) and World Health Organization (WHO). The IAEA and WHO evidence differed little from previous statements on the issue. The report was largely split between states concerned about depleted uranium's use, such as Finland, Cuba, Japan, Serbia, Argentina, and predominantly NATO members, who do not consider the use of depleted uranium munitions problematic. In December 2008, 141 states supported a resolution requesting that three UN agencies: United Nations Environment Programme (UNEP), WHO and IAEA update their research on the impact of uranium munitions by late 2010—to coincide with the General Assembly's 65th Session, four voted against, 34 abstained and 13 were absent. As before Britain and France voted against the resolution.
=== Weight regain === Weight regain is common upon discontinuation of weight loss medications, and long-term therapy may sometimes be required for sustained weight loss. After stopping treatment with GLP-1 agonists such as semaglutide, liraglutide and tirzepatide, people regain on average more than half (50–70%) of the lost weight within 1 year. People return to their previous weight within a year and a half after stopping anti-obesity medications.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.